# US 2005/0033024 A1 · Nucleic acid encoding eosinophil eotaxin receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0033024 A1
- Document ID: US20050033024A1
- Status: Published application
- Kind: A1
- Application number: 10/767,521
- Filed: 2004-01-29
- Published: 2005-02-10
- Earliest claimed: 1996-04-26
- Inventors: Bruce Daugherty; Julie Demartino; Salvatore Siciliano; Martin Springer
- Web page: https://patentgrep.com/patent/US20050033024A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C07K 14/7158: {for chemokines}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/158: Expression markers
- G01N 2333/715: for cytokines; for lymphokines; for interferons
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

## Claims

### Claim at position 1

1-35. (Canceled)

### Claim 36

An isolated nucleic acid which encodes a human eosinophil eotaxin receptor receptor, said nucleic acid having the nucleotide sequence as set forth in SEQ ID NO:2.

### Claim 37 (depends on 36)

The nucleic acid of claim 36 which further comprises the nucleotide sequence as set forth in SEQ ID NO:3.

### Claim 38 (depends on 36)

The nucleic acid of claim 36 which further comprises the nucleotide sequence as set forth in SEQ ID NO:4.

### Claim 39

A vector comprising a nucleic acid which encodes a human eosinophil eotaxin receptor receptor, said nucleic acid having the nucleotide sequence as set forth in SEQ ID NO:2.

### Claim 40 (depends on 39)

The vector according to claim 39 which is selected from the group consisting of: plasmids, modified viruses, yeast artificial chromosomes, bacteriophages, cosmids and transposable elements.

### Claim 41 (depends on 39)

An isolated mammalian host cell comprising the vector according to claim 39.

### Claim 42 (depends on 41)

The host cell of claim 41 which is from the AML14.3D10 cell line.

### Claim 43

A method to determine the presence of a compound which binds to a human eosinophil eotaxin receptor comprising:
(a) introducing a nucleic acid which encodes the human eosinophil eotaxin receptor which comprises the nucleotide sequence (SEQ ID NO:2) into a cell under conditions so that eosinophil eotaxin receptor is expressed;
(b) introducing a detector molecule or a nucleic acid encoding a detector molecule into the cell, wherein the detector molecule is directly or indirectly responsive to a eosinophil eotaxin-ligand binding event;
(c) contacting the cell with a compound suspected of binding to the eosinophil eotaxin receptor; and
(d) determining whether the compound binds to the eosinophil eotaxin receptor by monitoring the detector molecule.

### Claim 44 (depends on 43)

The method of claim 43 wherein the result of step (d) is compared to that obtained using a known ligand of the eosinophil eotaxin receptor.

### Claim 45 (depends on 44)

The method of claim 44 wherein the known ligand of the eosinophil eotaxin receptor is eotaxin.

### Claim 46 (depends on 44)

The method of claim 44 wherein the known ligand of the eosinophil eotaxin receptor is RANTES.

### Claim 47 (depends on 44)

The method of claim 44 wherein the known ligand of the eosinophil eotaxin receptor is MCP-3.

### Claim 48 (depends on 43)

The method of claim 43 wherein the eosinophil eotaxin receptor is expressed in a host cell which does not naturally express the human eosinophil eotaxin receptor

### Claim 49 (depends on 48)

The method of claim 48 wherein the host cell is from the AML14.3D10 cell line.
